The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms with IBM’s consulting and hybrid cloud expertise.SAN JOSE, Calif.--(BUSINESS ...
Ebenbuild GmbH, a Munich-based deep-tech healthcare company, today announced the publication of a peer-reviewed ...
The Agibot G2 is the first humanoid robot to get a job alongside humans on a high-speed electronics production line, Agibot ...
The global Industry 5.0 market is witnessing a transformative shift as manufacturing sectors evolve from pure automation ...
Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...
The report provides an extensive analysis of market trends and factors driving the growth of adhesive dispensing equipment ...
A team of researchers in the Netherlands has proposed a new way of designing computer models of the brain—an approach that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results